Bisphosphonates – A review

Slides:



Advertisements
Similar presentations
©American Society of Clinical Oncology All rights reserved - American.
Advertisements

British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.
Palliative care Emergencies Guidance for General Practice Western Area 2. Hypercalcaemia October Western Trust Primary Palliative Care Team Foyle.
King Abdul Aziz University Faculty Of Pharmacy
Prof. Robert Coleman, MD, FRCP Cancer Research Centre
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
Osteoporosis Jiří Slíva, M.D.. Osteoporosis §a bone disease that is characterized by progressive loss of bone density and thinning of bone tissue §higher.
Bone Diseases and Abnormalities Jake Turner and Roger Deering.
Carol S. Viele RN MS Clinical Nurse Specialist Hematology-Onc-BMT UCSF
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
1Stopeck A et al. Proc SABCS 2010;Abstract P
Renal Safety of Zoledronic Acid in Patients With Breast Cancer.
Denosumab in bone metastasis of cancer and hypercalemia Supervisor: 趙大中 大夫 Reporter: 郭政裕 總醫師.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.
DRUGS THAT AFFECT BONE MINERAL HOMEOSTASIS
Adult Medical-Surgical Nursing Musculo-skeletal Module: Pagets Disease.
Bisphosphonates in renal patients Supervised by : Prof. Ahmed Gaber Presented by : Noha Alaa El Dine Pharm D student.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
American Association of Oral and Maxillofacial Surgeons Osteonecrosis Guidelines Biochemical and molecular mechanisms of action of bisphosphonates Michael.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Adult Medical-Surgical Nursing Musculo-skeletal Module: Osteomalacia.
Chemotherapy Audit  Audit of patients who died within three months of their last dose of chemotherapy at Airedale General Hospital  The records of 50.
CC39/11-1 ZOMETA ® in Prostate Cancer and Solid Tumors Other Than Prostate Cancer and Breast Cancer: Placebo-Controlled Trials Matthew Smith, MD, PhD Massachusetts.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Bisphosphonates (BP)
Bisphosphonates effectively manage bone complications from cancer
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
Bondronat achieves better outcomes in metastatic bone disease Ingo Diel CGG-Klinik GmbH Mannheim, Germany.
Osteoporosis Armed Forces Academy of Medical Sciences.
Core Benefit/Risk (CR)
Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
D-1 Bisphosphonate Bone Metastases Trials Proportion of Patients With Any SRE § (12, 010) Patients, % TreatmentN 3 mo6 mo9 mo12 mo Pamidronate Study 12.
IN-1 Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002 C.
Evaluating the Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Patients with Multiple Myeloma: Results of the Medical Research Council.
HYPERCALCAEMIA Definiton an elevated ionised calcium concentration needs correction for low albumin (protein bound) but lab will usually report corrected.
REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.
CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Julie R. Gralow, MD Professor, Medical Oncology University of Washington School of Medicine Director, Breast Medical Oncology Seattle Cancer Care Alliance.
Bone matters in lung cancer T. Brodowicz, K. O’Byrne & C. Manegold Annals of Oncology 23: 2215–2222, 2012 R3 김승민 /Prof 정재헌.
Bone Health Secondary Breast Cancer
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Chapter 85: Treatment and Prevention of Bone Metastases and Myeloma Bone Disease Jean-Jacques Body.
Osteoporosis. Background Osteoporosis is disorders of the bone, characterized by progressive loss of bone mass and skeletal fragility. Patients with osteoporosis.
The role of bisphosphonates in the treatment of bone metastases of genitourinary tumors Nuno Gil WHAT YOU HAVE TO KNOW XIV WORKSHOP ON ONCOLOGICAL UROLOGY.
Osteoclast Inhibitors in Malignancy
EVOLUZIONE DEL RAPPORTO COSTO/EFFICACIA DELLA
Drugs Affecting Calcium Levels and Bone Mineralization
Natural History and Treatment of Bone Complications in Prostate Cancer
Buy Fosamax - Get Relief from Bone Disease
PARATHYROID AND CALCIUM HOMEOSTASIS
Drugs for osteoporosis (download the lecture from
AN OVERVIEW OF THE BONE METASTASES PROGRAM
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
Osteoporosis Definition
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
Natural History and Treatment of Bone Complications in Prostate Cancer
STOHN BONJ Process development
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Pharmacology of parathyroid hormone, vitamin D and calcitonin
Pathophysiology of Bone Metastases in Prostate Cancer
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
Osteoblasts Osteocytes Osteoclasts Cells of Bone Osteoblasts Osteocytes Osteoclasts.
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel  Filippo De Marinis, MD, Wilfried Eberhardt,
Presentation transcript:

Bisphosphonates – A review

Bisphosphonates 1st generation Etidronate 2nd generation Clodronate, Pamidronate 3rd generation Zoledronic Acid Ibandronate

Bisphosphonates Etidronate Clodronate Pamidronate Weak inhibitor of bone resorption Inhibits bone mineralisation and can produce osteomalacia Clodronate Acts as a direct poison to the osteoclasts Pamidronate The first nitrogen containing BP More potent than Clodronate Inhibits osteoclastic activity and the proliferation of precursor cells Zoledronic Acid /Ibandronate Further increase in anti-resorptive activity by substitution of the nitrogen atom from pamidronate with a methyl and pentyl residue

Bisphosphonates - Mechanisms of action Adsorbed onto hydroxyapatite crystals in the bone Inhibit the osteoclast mediated bone resorption and cause OC apoptosis (also aiding cancer therapy induced bone loss) Directly induce tumour cell apoptosis, reduce cell adhesion and invasion in pre-clinical models (?adjuvant role)

Cancer Induced Bone Pain (CIBP) Rich innervation of bone by primary afferents Tumours Alter the OB/OC balance (RANK,OPG) Induce a pronounced inflammatory infiltrate Release growth factors, cytokines and prostanoids causing ↓pH, ischaemia, apoptosis ►directly deforms the primary afferents ►activates nociceptors ►allows further resorption of bone by OC ►gross bone destruction and pathological fractures

Hypercalcaemia of malignancy (HCM) Mediated by soluble factors secreted by tumour cells and the immune system eg parathyroid hormone-related protein (PTHrP), prostaglandins and cytokines Stimulate excess bone resorption and release of calcium from the bone matrix PTPrP also stimulates increased renal Ca reabsorption

Indications Prevention and treatment of osteoporosis Treatment of Pagets disease Hypercalcaemia of malignancy Prevention of skeletal fracture events Ross 2003 Beneficial effects are time dependent; significant benefits were only seen after six months of treatment

Efficacy of bisphosphonates Prevention of skeletal related events (SRE) SRE’s include pathological #,SCC, RT to bone,surgery to bone and some studies include hypercalcaemia in this category Pamidronate and Clodronate proven in patients with breast and MM to ↓ SRE’s Pamidronate 90mg >Clodronate 1600mg (PO/IV)

Efficacy – SRE’s cont. Breast and MM patients 4mg Zometa (n=561) vs 90mg Pamidronate (n=555) Primary end point –Proportion of pts with at least 1 SRE Secondary endpoint – Time to first SRE 25/12 SRE Pam ≡ Zometa Zometa reduced the risk of developing skeletal complication by 16%>Pamidronate

Efficacy – SRE’s Prostate cancer patients Zometa Zometa 4mg vs placebo (n=643) After 24 months SRE Zometa 38% vs Placebo 49% (P=.028) Zometa significantly ↓ risk of skeletal complications by 36% vs placebo (P=0.002)

Efficacy – SRE’s Prostate Cancer patients (cont) Pamidronate 236 pts No more effective than placebo after 6/12 BUT Bone pain was Primary end point in this study, patients had more advanced disease (so difficult to compare this with previous study)

Efficacy – SRE’s Lung and other solid tumours Zometa 4mg IV vs placebo 9/12 Primary endpoint - % pts with a SRE Zometa ≡ Placebo 21/12 NSCLC and renal cell CA Taking secondary endpoints Zometa showed a 32% reduction in relative risk of SRE’s vs Placebo in the NSCLC group and 58% in the renal cell cancer group

Efficacy – SRE’s Ibandronate Trialled only in breast cancer patients Ibandronate 6mg IV vs placebo (1) Ibandronate 50mg PO vs placebo (2) Primary endpoint = SMPR (the no of 12/52 periods with skeletal complications ÷ total observation time) Secondary endpoints = multiple events analysis of skeletal events Both IV and PO ibandronate significantly ↓ the SMPR vs placebo Significant ↓ SRE’s vs placebo (approx 40%)

Efficacy – Bone pain and QOL Bone pain, analgesic use, QOL, functioning and performance statushave been used as secondary endpoint in some studies Clodronate Breast cancer pts – significant ↓ in pain and analgesic use MM patients – Significant ↓ Back pain However other studies in breast, prostrate and other neoplasms showed no benefit

Efficacy – Bone pain and QOL Pamidronate 1.Short term study (3/12) Pamidronate 90mg more effective than Clodronate 2. RCT(x2) Pamidronate vs placebo in breast cancer pts – pain scores increased in both groups over 2 yrs but significantly less so with Pamidronate

Efficacy –Bone pain and QOL Zoledronic Acid Breast Ca pts 1 Zometa 4mg = Pamidronate 90mg at reducing pain and analgesic scores @ 13/12 2 Zometa 4mg vs placebo. Significant ↓ pain scores in Zometa group after 1yr

Efficacy – Bone pain and QOL Ibandronate Breast cancer pts PO and IV ibandronate reduced pain scores on VAS for 2 yrs Also significant improvements in QOL, physical functioning vs placebo group. Cochrane review (Wong 2004) There is evidence to support the use of bisphosphonates in providing some pain relief. It is insufficient to recommend their use as first line or to define the most effective bisphosphonate or the relative effectiveness of bisphosphonates for different primary neoplasms

Safety considerations Hypocalcaemia PO bisphosphonates Nausea, epigastric pain and oesophagitis IV bisphosphonates Injection site reaction Flu-like syndrome Renal toxicity – may vary between agents because of differential protein binding ? Ibandronate safer? Osteonecrosis of the jaw

Practical recommendations for use Using early appears to prevent SRE’s ASCO recommend the routine use of IV pamidronate or Zoledronic acid in pts with breast cancer and radiological evidence of bone destruction Continue until there is a substantial decline in the pts performance status Body JJ (2006)– Start when lytic or mixed picture metastatic bone disease in weight bearing bones, painful sites correspond to areas of known disease, following first SRE

Future? Use of bone turnover markers esp as predictors of response “Burst” bisphosphonates to establish more quickly if a patients pain is likely to respond Use as an adjuvant because of anti-tumour properties – can they prevent bone metastases? Prevention of cancer-therapy-induced bone loss - Benefits for all patients even in early stages to preserve bone density?

References Urch C. The pathophysiology of cnacer-induced bone pain:current understanding Palliat Med 2004;18:267-274 Neville-Webbe HL The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliat Med 2003;17: 539-553 Mannix K et al Using bisphosphonates to cintrol the pain of bone metastaes: evidence-based guidelines for palliative care Palliat Med 2000;14:455-461

References (cont) Body JJ Bisphosphonates for malignancy-related bone disease: current status, future developments Support Care Cancer 2006;14:408-418